Ziphius LLC
June 16, 2025
Company Presentation
Infectious Disease and Vaccines
Ziphius, a Belgium/US-based private biotech company, is advancing a next-generation platform utilizing self-amplifying RNA (saRNA) and lipid nanoparticles (LNPs) to develop first and best in class medicines for infectious diseases, rare diseases, and oncology.
Since our founding in 2019, we have raised $43M and are now preparing to secure an additional $50M in 2025 to accelerate the development of our programs and reach our first clinical milestones. With a dedicated team of 65 professionals based in Belgium and the US (New York), Ziphius is committed to developing first- and best-in-class RNA medicines.
Pipeline:
1. Chlamydia Trachomatis vaccine
2. Pan-Corona vaccine
3. Cystic Fibrosis therapy
Milestones
Recent preclinical studies data in Pigs:
-Superior Humoral and CMI responses
-Ongoing NHP studies
Company HQ City:
New York
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
Chlamydia Trachomatis Vaccine
Pancorona Vaccine
Cystic fibrosis therapy
CEO
Chris Cardon - CEO
Year Founded
2019
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
-
When you expect your next catalyst update?
Non Human Primates study result
What is your next catalyst (value inflection) update?
March, 2025
Website
https://ziphius.org/
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}